Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

Inclusion criteria

• Individuals who voluntarily decide to participate in this study and provide written informed consent

• Healthy male and female adult at the age of 19 to 50 years (Part A)
• Healthy male and female adult at the age of 19 to 75 years (Part B)
• Individuals who are available for all visit procedures including telephone visits during the study period

Exclusion criteria

• COVID-19 positive based on RT-PCR using upper respiratory tract or lower respiratory tract sampling or COVID-19 antibody positive
• History of SARS-CoV, MERS-CoV or SARS-CoV-2 infection
• History of vaccination against SARS-CoV, MERS-CoV or SARS-CoV-2
• Immune system disorders including immunodeficiency disease
• Clinically significant abnormalities in clinical laboratory test, ECGs and chest X-ray during screening in the opinion of the investigator
• Fever within 3 days prior to screening or serious acute or chronic infection within 7 days prior to screening requiring systemic antibiotics or antivirals
• Evidence or history of serious acute, chronic, or progressive disease which, in the opinion of the investigator, makes the individual ineligible for the study
• History of severe allergic reactions or severe hypersensitivity reactions to the IP or any of its components
• History of therapy that might affect immunity: treatment with immunosuppresants or immune modifying drugs, anticancer therapy, or radiotherapy within 3 months prior to screening
• Women of childbearing potential who do not agree to use medically allowed methods of contraception or to be heterosexually inactive until 60 days after the last dose of the IP
• Pregnant or breastfeeding woman
• Treatment with other IPs within 6 months prior to participation in this study
• Other reasons including medical reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator